- Home
- NFE vs AARD Comparison
NFE vs AARD Comparison
Compare NFE & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NFE | AARD |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.4M | 281.1M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | NFE | AARD |
|---|---|---|
| Price | $1.07 | $5.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 10 |
| Target Price | $7.70 | ★ $19.63 |
| AVG Volume (30 Days) | ★ 5.5M | 325.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,364,860,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $79.17 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.98 | $4.74 |
| 52 Week High | $12.59 | $17.94 |
Technical Indicators
Market Signals| Indicator | NFE | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 41.38 | 24.24 |
| Support Level | $1.03 | $4.74 |
| Resistance Level | $1.40 | $15.88 |
| Average True Range (ATR) | 0.09 | 0.54 |
| MACD | -0.00 | -0.55 |
| Stochastic Oscillator | 8.57 | 12.99 |
Price Performance
Historical ComparisonAbout NFE New Fortress Energy Inc.
New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.